Similar articles

• FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.

  [No authors listed] [No authors listed] AIDS Alert. 2007 Sep;22(9):103. AIDS Alert. 2007. PMID: 18411462 No abstract available.
• FDA advisory committee approves Selzentry.

  [No authors listed] [No authors listed] AIDS Patient Care STDS. 2009 Nov;23(11):987. AIDS Patient Care STDS. 2009. PMID: 19938371 No abstract available.
• Something new under the sun. Maraviroc poised for approval.

  Huff B. Huff B. GMHC Treat Issues. 2006 Aug-Dec;20(8-12):1-4. GMHC Treat Issues. 2006. PMID: 17569160 No abstract available.
• Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.

  Kast RE. Kast RE. J Clin Pharm Ther. 2010 Dec;35(6):657-63. doi: 10.1111/j.1365-2710.2009.01148.x. J Clin Pharm Ther. 2010. PMID: 21054456 Review.
• Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.

  Horster S, Goebel FD. Horster S, et al. Infection. 2006 Apr;34(2):110-3. doi: 10.1007/s15010-006-6206-1. Infection. 2006. PMID: 16703305 Review. No abstract available.